Last update 28 May 2025

CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)

Overview

Basic Info

Drug Type
CAR-NK
Synonyms
CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells
Target
CD5 x IL15R
Action
agonists, inhibitors
Mechanism
IL15R agonists(Interleukin-15 receptors agonists), T-cell surface glycoprotein CD5 inhibitors
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Mantle cell lymphoma refractoryMixed phenotype acute leukemiaPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma+ [3]
Inactive Indication-
Originator Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Organization
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
NCT05110742
/ RecruitingPhase 1/2IIT
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
100 Clinical Results associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Deals associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma refractoryPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Mixed phenotype acute leukemiaPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Precursor T-Cell Lymphoblastic Leukemia-LymphomaPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Prolymphocytic LeukemiaPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Richter's syndromePhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Small Lymphocytic LymphomaPhase 2
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
22 Apr 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free